Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib in Advanced Solid Tumors and TNBC
NCT03654547Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Jan 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of tinengotinib in solid tumor (advanced stage) and triple-negative breast cancer (TNBC) (2 arms), sponsored by TransThera Biosciences. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Started Jan 2019; status: completed.
02
Drugs
tinengotinib
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03654547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654547.